FREE Daily Stock Alerts From Stock-PR.com
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that the Company has initiated patient dosing in segment 2 of its Phase 2 clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) for genotype 1 treatment naive HCV-infected patients. ACH-1625, discovered and advanced by Achillion, is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The clinical trial has advanced into the second segment of a Phase 2a, randomized, double-blind trial evaluating the safety, tolerability and antiviral activity of oral ACH-1625 in combination with standard of care (SOC) consisting of pegylated interferon alfa-2a and ribavirin. Patients will be randomized to receive once daily doses of 200 mg, 400 mg or 800 mg of ACH-1625 in combination with SOC for 12 weeks of dosing. Patients will continue to receive an additional 12 weeks of pegylated interferon alfa-2a and ribavirin and eligible to discontinue treatment at week 24 if they achieve extended rapid virologic response (eRVR) at week 12. Patients who do not achieve an eRVR will continue to receive SOC until week 48.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. Achillion Pharmaceuticals, Inc. was founded in 1998 and is based in New Haven, Connecticut.
National Health Partners, Inc. (OTC:NHPR)
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called "CARExpress."
Hypnotherapy is often a long practiced tradition which has been studied and utilized in quite a few distinct types. In modern times, this therapy is becoming additional regulated and accredited, which indicates it can be both more trustworthy and successful for a multitude of therapy requires. Although you'll find nonetheless people who are skeptics in regards to the effects of hypnosis, the numbers are lessening as a result of the excellent achievement this field has witnessed within the latest years.
Any person who wishes to make changes in their life can probably benefit from hypnosis. Although some people are definitely more open to the idea of suggestion and relaxing into a trance state, most people can be put into hypnosis if they are interested in the idea. Because modern day hypnotherapists generally adhere to codes of ethics that require them to only use hypnosis when a patient is seeking help and to only suggest proper behaviors, hypnotherapy is safe in most cases.
Through National Health Partners' national network of holistic, complementary and alternative health providers, members receive savings of 25% on a wide range of over 20 modalities of care. Some of these modalities are:
Swedish Massage, Acupressure, Acupuncture and Oriental Medicine, Alexandre Technique, Aromatherapy, Craniosacral Therapy, Detoxitication, Herbology, Homeopathy, Hypnotherapy, Massage Therapy, Naturopathy, Oriental Bodywork, Polarity Therapy, Qi Gong, Reflexology, Reiki, Rolfing, Rosen Method, Shiatsu, Tai Chi, Tui Na
CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna. The company's primary target customer group is the 47 million Americans who have no health insurance of any kind. The company's secondary target customer group includes the millions of Americans who lack complete health insurance coverage.
National Health Partners, Inc., announced the recent signing of two new significant marketing agreements. These two clients provide very different opportunities and continue to expand the reach of CARExpress into new marketplaces.
By launching their own unique internet marketing program, the first group should be able to provide a widespread push into the on-line market to produce an excellent volume of new CARExpress sales into the pipeline. In addition, the second group offers a reach into the wholesale marketplace where CARExpress will be wrapped into other programs to enhance the value of the overall package to the consumer. They would consider this non-traditional business and a great opportunity to expand their reach as well as recognition of the CARExpress program nationwide.
The company plans to announce the rollout of these new marketing campaigns as well as several others over the next few weeks.
For more information please visit official website of NHPR: www.nationalhealthpartners.com.
Cleantech Transit Inc (OTCPK:CLNO)
Cleantech Transit Inc. is in the business of producing and conserving power. It produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind.
Solar panels give off no pollution; the only pollution produced as a result of solar panels is the manufacturing of these devices in factories, transportation of the goods, and installation. The production of energy from the use of fossil and some renewable fuels (e.g. wind turbines) can be noisy, yet solar energy produces electricity very quietly.
One of the great pros of solar energy is the ability to harness electricity in remote locations that are not linked to a national grid. A prime example of this is in space, where satellites are powered by high efficiency solar cells. The installation of solar panels in remote locations is usually much more cost effective than laying the required high voltage wires.
Solar energy can be very efficient in a large area of the globe, and new technologies allow for a more efficient energy production on overcast/dull days. Solar panels can be installed on top of many rooftops, which eliminate the problem of finding the required space for solar panel placement. Another great pro of solar energy is the cost. Although the initial investment of solar cells may be high, once installed, they provide a free source of electricity, which will pay off over the coming years. The use of solar energy to produce electricity allows the user to become less dependent on the worlds fossil fuel supplies.
The production of electricity from geothermal energy sources can be a highly efficient method to generate a source of clean and renewable energy. Location is key for the development of an efficient geothermal power station, and therefore, significant levels of electricity can only be generated in certain areas. There are only a handful of locations across the world that is capable of producing viable and efficient levels of electricity from geothermal energy sources. As a result of this, in 2007, less than 1% of the worlds electricity supply was produced from geothermal sources. To harness geothermal energy and transform this into electricity, geothermal power stations are designed in a variety of ways. The three main power plant designs which utilize geothermal as an energy source are; "dry steam", "flash steam", and "binary-cycle" power stations.
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. Cleantech Transit Inc has expanded its focus to invest directly in specific green projects that could maximize shareholder value. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech Transit Inc. has selected to invest in Phoenix Energy (www.phoenixenergy.net).
Cleantech Transit, Inc. (OTCPK:CLNO) is pleased to announce it has met its funding requirement to secure the Company's ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
For more information about CLNO, visit www.cleantechtransitinc.com
Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, and Robert Lollini, Chief Financial Officer and Treasurer, will participate in one-on-one meetings with investors registered to attend the Stifel Nicolaus 2011 Orphan Drug One-on-One Conference, to be held July 12, 2011, in New York City. The conference will not be webcast. Myrexis' most recent investor presentation is available on the Company's Web site, www.myrexis.com.
Myrexis, Inc. is a biotechnology company focused on developing and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and pre-clinical product candidates.
Asta Funding, Inc. (Nasdaq:ASFI) a consumer receivable asset management and liquidation company, announced that its Board of Directors has authorized a share repurchase program for up to $20,000,000 of the Company's common stock. Gary Stern, CEO of the Company, commented, "Our open market repurchases by the Company over the course of the next year reflects the Board of Director's continued confidence in our business strategy and growth prospects as we continue to seek portfolio investments and acquisitions in the financial services industry. Based on current market prices, we believe the repurchase program is prudent and in the best interests of our shareholders," further stated Mr. Stern.
Asta Funding, Inc., together with its subsidiaries, engages in purchasing, managing, and servicing distressed consumer receivables in the United States. Asta Funding, Inc. was founded in 1994 and is based in Englewood Cliffs, New Jersey.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (OTC:NHPR). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (OTCPK:CLNO).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup